Takeda Tests New Highs, But Struggles To Find Entyvio Successor (NYSE:TAK)

Core Insights - Takeda Pharmaceutical Company Limited (TAK) was previously discussed in May, indicating a challenging outlook for 2025 as the stock was underperforming [1] Company Overview - The company is currently facing difficulties, with expectations of a tough fiscal year ahead [1] Analyst Background - The analysis is conducted by an experienced individual with over 20 years in foreign policy research and 25 years in investment analysis, focusing on deep-discount value plays [1]